Physician profile
Allen A Freestone
NPI 1801850755
$9,052.14
in general payments reported to CMS, 2019-2025
64 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $1,161 · 2021: $1,360 · 2022: $1,441 · 2023: $1,465 · 2024: $971 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,887.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,372.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $860.28 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $800.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $723.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $715.71 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $497.32 | 2019-2023 | Gardasil 9, Rotateq, M-M-R II |
| Amarin Pharma, INC. | $411.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $374.20 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $328.30 | 2019-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $295.75 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $193.09 | 2019-2024 | Spravato |
| Pfizer INC. | $186.24 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $183.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.45 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.13 | 2022-2025 | Caplyta |
Show all 62 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Freestone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.